Cryocompression May Mitigate Chemo-Induced Neuropathy in Gynecologic Cancers

Video

Investigators report that most patients with gynecologic cancers were able to tolerate cryocompression to help manage chemotherapy-induced neuropathy, according to an expert from Duke University Medical Center.

Cryocompression may help to prevent peripheral neuropathy related to chemotherapy for patients diagnosed with gynecologic cancers without additional burden, according to Mary Katherine Montes de Oca, MD.

During The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer, CancerNetwork® spoke with Montes de Oca, an Obstetrics and Gynecology resident at Duke University Medical Center, about data from a study evaluating the efficacy and patient-reported outcomes of cryocompression in preventing peripheral neuropathy following chemotherapy for gynecologic cancers as well as patient-reported.

In the self-controlled trial, over 70% of patients reported cryocompression was very tolerable with each cycle, and over 80% “agreed” or “strongly agreed” that cryocompression was acceptable and planned to continue with the intervention during future chemotherapy. Additionally, patients undergoing cryocompression were 39% less likely to report Patient Neurotoxicity Questionnaire grade of C or less symptoms of peripheral neuropathy compared with a control group of patients who did not undergo cryocompression.

Transcript:

We found that cryocompression therapy significantly prevented subjective symptoms of neuropathy. We didn’t find any differences in objective neuropathy between groups, and we found that patients overall were able to tolerate the cryocompression really well.

There’s a theoretical concern of frostbite from the ice on the hands and feet. We didn’t have any adverse [effects] from use of the cryocompression. There were 2 patients who weren’t able to tolerate the treatment. But the compression therapy can also allow for a barrier between the patient’s fingertips and the ice.

I hope that [my colleagues] take away that cryocompression can prevent chemotherapy-induced peripheral neuropathy in patients with gynecologic cancer. Hopefully, it is something that is easy, accessible, and [is something] that can be recommend to patients without creating additional burden on them during chemotherapy.

Reference

Montes de Oca MK, Unnithan S, Erkanli AE, et al. Use of cryocompression to reduce peripheral neuropathy in gynecologic cancer: a randomized controlled trial. Presented at: 2023 SGO Annual Meeting on Women’s Cancer; March 25-28, 2023; Tampa, Florida.

Recent Videos
An “avalanche of funding” has propelled the kidney cancer field forward, says Jason Muhitch, PhD.
Kidney cancer advocacy efforts have spread the urgency and importance of funding research in the field to members of Congress.
Advocacy efforts have yielded a dramatic increase in kidney cancer research, according to Elizabeth P. Henske, MD.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Related Content